ERBB2 and breast carcinoma: In our cohort, compared to that in tumors without prior systemic treatment, VM significantly increased in cancer cell clusters that had survived Tzm-based chemotherapy (14/24 cases; 58%), suggesting that VM is associated with more malignant phenotypes in HER2+ breast cancer.